HK Stock Movement | TRANSCENTA-B (06628) Rises Over 4% as Ozekibart to Submit U.S. Indication Application by Mid-2026-To The Moon - Tiger Brokers Online Investing Community

Like
Comment
Favorite

HK Stock Movement | TRANSCENTA-B (06628) Rises Over 4% as Ozekibart to Submit U.S. Indication Application by Mid-2026

Stock News10-31

TRANSCENTA-B (06628) surged nearly 10% intraday before settling at a 4.75% gain to HK$3.09, with a turnover of HK$4.006 million. The company announced that its partner, Inhibrx Biosciences (INBX.US), recently reported positive primary results from a registrational clinical study of ozekibart, a tetravalent death receptor 5 (DR5) agonist antibody. The study evaluated ozekibart as a monotherapy versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. Based on these results, Inhibrx plans to submit a marketing authorization application for the chondrosarcoma indication to U.S. regulators by June 2026. TRANSCENTA-B holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1179011069?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 14:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179011069","market":"fut","top_or_hot":-1,"title":"HK Stock Movement | TRANSCENTA-B (06628) Rises Over 4% as Ozekibart to Submit U.S. Indication Application by Mid-2026","media":"Stock News","content":"<p>TRANSCENTA-B (06628) surged nearly 10% intraday before settling at a 4.75% gain to HK$3.09, with a turnover of HK$4.006 million. The company announced that its partner, Inhibrx Biosciences (INBX.US), recently reported positive primary results from a registrational clinical study of ozekibart, a tetravalent death receptor 5 (DR5) agonist antibody. The study evaluated ozekibart as a monotherapy versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. Based on these results, Inhibrx plans to submit a marketing authorization application for the chondrosarcoma indication to U.S. regulators by June 2026. TRANSCENTA-B holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | TRANSCENTA-B (06628) Rises Over 4% as Ozekibart to Submit U.S. Indication Application by Mid-2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | TRANSCENTA-B (06628) Rises Over 4% as Ozekibart to Submit U.S. Indication Application by Mid-2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-31 14:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TRANSCENTA-B (06628) surged nearly 10% intraday before settling at a 4.75% gain to HK$3.09, with a turnover of HK$4.006 million. The company announced that its partner, Inhibrx Biosciences (INBX.US), recently reported positive primary results from a registrational clinical study of ozekibart, a tetravalent death receptor 5 (DR5) agonist antibody. The study evaluated ozekibart as a monotherapy versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. Based on these results, Inhibrx plans to submit a marketing authorization application for the chondrosarcoma indication to U.S. regulators by June 2026. TRANSCENTA-B holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1179011069","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179011069","pubTimestamp":1761890770,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TRANSCENTA-B (06628) surged nearly 10% intraday before settling at a 4.75% gain to HK$3.09, with a turnover of HK$4.006 million. The company announced that its partner, Inhibrx Biosciences (INBX.US),...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","06628":"创胜集团-B"},"translate_title":"港股走势|创胜-B(06628)涨超4%Ozekibart将于2026年中提交美国适应症申请","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06628":1},"content_text":"TRANSCENTA-B (06628) surged nearly 10% intraday before settling at a 4.75% gain to HK$3.09, with a turnover of HK$4.006 million. The company announced that its partner, Inhibrx Biosciences (INBX.US), recently reported positive primary results from a registrational clinical study of ozekibart, a tetravalent death receptor 5 (DR5) agonist antibody. The study evaluated ozekibart as a monotherapy versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. Based on these results, Inhibrx plans to submit a marketing authorization application for the chondrosarcoma indication to U.S. regulators by June 2026. TRANSCENTA-B holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}